LifeBridge Highlights Serious Tobacco-Related Health Risks in New Report for 2026

In a striking report released in early February, LifeBridge is calling attention to the escalating health threats posed by tobacco products, especially as traditional support systems for smokers face significant changes. The American Lung Association's 24th annual "State of Tobacco Control" report paints a concerning picture of the ongoing public health crisis associated with tobacco use, which continues to be the leading cause of preventable death in the United States, resulting in over 490,000 fatalities each year. Despite a reported decline in cigarette smoking among U.S. adults to 11.6% in 2022, many millions still struggle with nicotine addiction.

Recent shifts in federal tobacco policies have alarmed health advocates. Harold Wimmer, ALA President and CEO, articulated grave concerns about the potential impact on prevention efforts, stating that these changes undermine access to vital quitline counseling and essential state-funded prevention programs. As legislative changes threaten to erode decades of progress in tobacco control, Wimmer emphasized the urgent need for both states and individuals to engage actively in combating tobacco use, especially among youth who are at risk of being introduced to new and harmful tobacco products.

Ladislav Cizmarik, CEO and co-founder of LifeBridge, echoed this sentiment, stressing the crucial role that businesses can play in addressing this epidemic. Cizmarik remarked, "We recognize the extensive harm caused by smoking. It is imperative for businesses to contribute effectively to solutions that assist individuals in reclaiming their health and autonomy from harmful habits."

In response to these alarming trends, LifeBridge has introduced iQair for Smokers, a nutraceutical designed to support lung health for those looking to quit smoking. Emphasizing the importance of merging natural wellness strategies with conventional medical interventions, Cizmarik noted the formulation's reliance on specific natural ingredients known for their beneficial properties. The product includes high doses of Vitamin D3, Cordyceps extract, and Boswellia serrata extract, which are heralded for their roles in enhancing respiratory strength and immune defense.

"iQair for Smokers is engineered to fortify lung resilience while promoting long-term respiratory well-being," Cizmarik explained. This innovative approach aims to provide a supportive pathway for smokers in their journey to overcome addiction and repair lung damage.

LifeBridge, founded in 2018 in Slovakia, leverages extensive experience in the pharmaceutical sector. With a focus on nutraceutical solutions throughout Slovakia, the Czech Republic, and Hungary, the company's founders have over three decades of executive experience in major pharmaceutical firms such as Roche, Pfizer, and Bayer. By drawing on this wealth of knowledge, LifeBridge aims to address prevalent health concerns holistically, ranging from allergies to immune system issues.

As federal tobacco policies evolve, LifeBridge's efforts highlight the importance of maintaining robust anti-smoking initiatives and supporting individuals in their health journeys. With the launch of products like iQair for Smokers, the company demonstrates a commitment to harnessing natural solutions to aid in overcoming the tobacco crisis, signaling a hopeful path forward amid heightened challenges. For those looking to improve their health post-smoking, LifeBridge is not just a product; it represents a commitment to rebuilding lives and fostering healthier communities.